AOM Expands Infusion Offerings with Addition of IVIG from Kedrion Biopharma
ARLINGTON, Texas–(BUSINESS WIRE)–AOM Infusion (“AOM”), a leading provider of specialty infusion and pharmacy services for chronic and complex conditions, has been selected by Kedrion Biopharma as a limited distribution network specialty pharmacy for YIMMUGO® (Immune Globulin Intravenous, Human-dira, 10%), an immune globulin (Ig) liquid for the treatment of primary humoral immunodeficiency (PI), expanding AOM’s IVIG offerings.
YIMMUGO is a 10% immune globulin liquid, indicated for the treatment of primary humoral immunodeficiency (PI), including but not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), and severe combined immunodeficiencies (SCID) in patients 2 years of age and older. Patients treated with YIMMUGO® receive one infusion every three to four weeks, administered by a trained healthcare professional at home or at an AOM infusion center. Dosage and infusion schedules depend on the patient’s weight and response to YIMMUGO®.
Kedrion Biopharma selected AOM Infusion for its national reach and expertise in intravenous immunoglobulin (IVIG) therapy across more than 80 chronic and complex conditions, with a strong focus on PI.
“AOM Infusion’s commitment to patient-centered care and operational excellence made them an ideal addition to our limited distribution network of specialty pharmacies,” says Bob Rossilli, Chief Commercial Officer at Kedrion Biopharma Inc. “Partnering with AOM enables us to expand reliable access to critical treatments for patients nationwide.”
AOM continually evaluates and integrates the latest high-quality Ig therapies to ensure patients have access to the most advanced treatment options. As a trusted partner to physicians, AOM accelerates access to therapy and provides full-spectrum support, including clinical oversight, coordination, and outcomes tracking.
“We value the trust Kedrion has placed in AOM Infusion to provide this advanced IVIG therapy, expanding the safe and effective options available to our patients,” says Karmen Stowe, Vice President of Trade Relations & Supply Chain. “Our 30+ years of Ig expertise help us remain highly selective and efficient in matching the right brand to the right patient. Our focus is always on improving health outcomes and helping patients live with greater confidence and quality of life.”
As a designated limited distribution specialty pharmacy for YIMMUGO®, AOM further expands its IVIG capabilities and supports timely access to vital infusion therapies in collaboration with healthcare providers, health systems, and payors nationwide.
For more information about YIMMUGO®, visit: https://www.yimmugo.us/.
For more information about AOM Infusion, visit: https://aominfusionrx.com/.
About AOM Infusion
AOM Infusion has been a leader in infusion care for 30 years, with a national pharmacy licensure footprint. The company specializes in the care of patients with chronic conditions who may require a more complex level of treatment, and has deep experience providing therapy for over 80 chronic conditions. AOM Infusion is focused on expanding its therapy solutions and investing in innovative platforms to deliver state-of-the-art care to more patients across the country.
About Kedrion Biopharma
Kedrion Biopharma collects and fractionates blood plasma to produce and distribute plasma-derived therapies for rare, ultra-rare, and debilitating conditions like Coagulation and Neurological Disorders, Immunodeficiencies, and Rh sensitization. Kedrion employs approximately 5,200 people worldwide, and its industrial network includes 68 plasma collection centers in the United States and 8 in the Czech Republic, and 7 production facilities across 5 countries. Kedrion is committed to creating a world where science and care know no bounds, partnering with the medical-scientific community, institutions, patient advocacy groups, and research bodies to foster innovation and improve care.
INDICATION
YIMMUGO (immune globulin intravenous, human – dira), is a 10% immune globulin liquid, indicated for the treatment of primary humoral immunodeficiency (PI) including but not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID) in patients 2 years of age and older.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE
Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO [see Warnings and Precautions (5.3), Patient Counseling Information (17)].
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose [see Warnings and Precautions (5.4)].
For patients at risk of thrombosis, renal dysfunction, or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Dosage and Administration (2.1, 2.3), Warnings and Precautions (5.3)].
For more information about YIMMUGO®, please see the full prescribing Information.
Contacts
AOM Infusion Media
Kyra Barker
[email protected]
